INFO & CONTACTS:  +39 02 2390 1

A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, + Best SupportiveCare Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer

Phase: Phase II-III clinical trials

Principal Investigator: Dott. Procopio Giuseppe

Main Facility: Oncologia Medica Genitourinaria

Drug: PASRITAMIG (BISPECIFOC KLK-2 / CD3 ANTIBODY)

Pathologies: Prostate tumors

A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cellredirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer

Last update: 20/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe